<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02801695</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0475</org_study_id>
    <nct_id>NCT02801695</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Citrulline Supplementation on the Delay of Delivery for Women Hospitalized for Pre-eclampsia (CITRUPE)</brief_title>
  <acronym>CITRUPE</acronym>
  <official_title>Evaluation of the Efficacy of Citrulline Supplementation on the Delay of Delivery for Women Hospitalized for Pre-eclampsia (CITRUPE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-eclampsia (PE) complicates 2-8 % of pregnancies and is associated with high maternal and&#xD;
      fetal morbidity and mortality. The early clinical manifestations are the occurrence of a&#xD;
      maternal blood pressure and proteinuria. Placental dysfunction impairs the nutrient supply to&#xD;
      the fetus, and may be the cause of an intrauterine growth retardation (IUGR). This is a&#xD;
      disease that causes prematurity and currently the only known cure is delivery of the&#xD;
      placenta. Nitrogen monoxide (NO) regulates the placental blood flow. However, pre-eclampsia&#xD;
      is directly related to a failure of placental NO production. In this context, several&#xD;
      clinical trials have tested the effect of NO donors such as L- arginine. However,&#xD;
      supplementation with L -Arginine in a randomized trial in Nantes, has proved to be&#xD;
      ineffective in severe vascular IUGR.&#xD;
&#xD;
      Citrulline is a natural aminoacid precursor to arginine and in contrast to L-arginine escapes&#xD;
      uptake in the liver and appears directly in the peripheral blood converted by the kidney in&#xD;
      arginine, released into the systemic circulation, Citrulline may therefore be more effective&#xD;
      in the treatment of pre-eclampsia.&#xD;
&#xD;
      This prospective, randomized, comparative and double-blinded study aims to prolong pregnancy&#xD;
      for patients with pre-eclampsia before 36 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2017</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of days between the therapeutic initiation and childbirth</measure>
    <time_frame>childbirth</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Pre-eclampsia</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>L-Citrulline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citrulline</intervention_name>
    <description>Citrulline supplementation</description>
    <arm_group_label>L-Citrulline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Lactose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt;= 18 years old&#xD;
&#xD;
          -  pregnant woman&#xD;
&#xD;
          -  singleton pregnancy&#xD;
&#xD;
          -  woman with pre-eclampsia (&lt;36 weeks) without indication of forthcoming extraction&#xD;
&#xD;
          -  subjects affiliated with an appropriate social security system&#xD;
&#xD;
          -  subjects out of context of guardianship&#xD;
&#xD;
          -  written signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 18 years old&#xD;
&#xD;
          -  isolated hypertension or isolated proteinuria&#xD;
&#xD;
          -  severe pre-eclampsia with indication of forthcoming extraction in emergency&#xD;
&#xD;
          -  term pregnancy &gt;= 36 Weeks when diagnosis is done&#xD;
&#xD;
          -  multiple pregnancy&#xD;
&#xD;
          -  lactose intolerance&#xD;
&#xD;
          -  context of guardianship&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobert Winer, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin (Maternité Port-Royal)</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 3, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-eclampsia</keyword>
  <keyword>citrulline</keyword>
  <keyword>pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

